Clinical Trials · NCT06858878
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Amgen
- Enrollment
- 1,105
- Start date
- Mar 2025
- Locations
- 187 sites, 13 countries
- Primary endpoint
- Percent Change from Baseline in Body Weight at Week 72